Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers

University of Missouri (MU)

Status: Enrolling

Conditions: Healthy; Carrier of Phenylketonuria

Treatments: Dietary Supplement: Phenylalanine (Phe); Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT07220265

2092228

R21HD115129-01A1 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The goal of this clinical trial is to advance our understanding of the cognitive and neurophysiologic sequelae associated with suboptimal phenylalanine (Phe) metabolism in heterozygyous carriers of phenylketonuria (PKU). The main questions it aims to answer are:

• Do PKU carriers experience prolonged elevations in brain Phe levels following oral ingestion of dietary Phe?
• Do PKU carriers experience disruptions in cognitive functioning following oral ingestion of dietary Phe?
• Do PKU carriers experience atypical brain activity following oral ingestion of dietary Phe? Researchers will compare PKU carriers and non-carriers following oral ingestion of dietary Phe and a placebo.

Participants will:

• Consume Phe or a placebo at two separate visits to our facility
• At each visit, they will complete a series of MRIs and cognitive tests throughout the day

Full description

Limitations inherent in past studies of phenylketonuria (PKU) carriers (e.g., poor genetic characterization of sample resulting in inclusion of homozygous non-PKU relatives, reliance on rudimentary or overly broad behavioral assessment tools) make it difficult to conclude the extent to which neurophysiologic and cognitive processes are affected in these individuals. To address this gap in the literature, we propose to conduct a double-blind crossover study in a sample of genetically-confirmed sample of 18 heterozygous PKU carriers and 18 non-carriers. A principled investigation of the effects of elevated phenylalanine (Phe) on neurocognition will involve participants performing an fMRI n-back WM task, resting state scan, and a battery of select cognitive tests at 3 timepoints: baseline (pre-load), 2 hours and 4 hours after starting oral administration of Phe or placebo. Blood and brain levels of Phe and Tyr will also be assessed at each timepoint.

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18-60 years
• For the PKU carrier group: Individuals who are the parent of an individual with PKU or who are otherwise have confirmed PKU carrier status (e.g., a sibling of someone with PKU who has had genetic testing done)
• For the non-carrier group: Individuals who do not have PKU or a family history of PKU

Exclusion criteria

• Obesity as defined by a body mass index (BMI) over 30*
• Taking oral contraceptives on the day of testing session*
• Positive cotinine urine test showing nicotine use
• History of major neurologic condition (e.g., multiple sclerosis, severe closed head injury, Parkinson's disease)) unrelated to PKU and known to adversely impact brain health and function
• Contraindications for safe MRI participation such as (a) pregnancy or plans to become pregnant during period of study enrollment; or (b) metallic objects inside the body (e.g., surgical staples left in the body following surgery, middle ear prosthesis, metal foreign objects lodged inside the eye, heart pacemakers).

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

36 participants in 2 patient groups

PKU Carriers

Other group

Description:

Heterzygous carriers of a pathogenic variant of the PAH gene associated with phenylketonuria (PKU)

Treatment:

Dietary Supplement: Placebo

Dietary Supplement: Phenylalanine (Phe)

Non-Carriers

Other group

Description:

Individuals who do not carry a pathogenic variant of the PAH gene

Treatment:

Dietary Supplement: Placebo

Dietary Supplement: Phenylalanine (Phe)